Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 20/20 | 0.64 |
| ▸ | GPR183 | P32249 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL386891 | 0.83 | GPR119 (0.59) | GPR119GPR183CYP3A4CYP2C19 | |
| SCHEMBL384915 | 0.83 | GPR119 (0.59) | GPR119GPR183CYP3A4CYP2C19 | |
| SCHEMBL19059470 | 0.82 | GPR119 (0.68) | GPR119GPR183CYP3A4CYP2C19 | |
| SCHEMBL388551 | 0.81 | GPR119 (0.59) | GPR119GPR183CYP3A4CYP2C19 | |
| SCHEMBL12474791 | 0.81 | GPR119 (0.67) | GPR119GPR183CYP3A4CYP2C19 | |
| SCHEMBL5779093 | 0.80 | GPR119 (0.74) | GPR119GPR183CYP3A4CYP2C19 | |
| SCHEMBL14634105 | 0.79 | GPR119 (0.77) | GPR119GPR183CYP3A4CYP2C19 | |
| SCHEMBL14634104 | 0.79 | GPR119 (0.77) | GPR119GPR183CYP3A4CYP2C19 | |
| SCHEMBL354846 | 0.79 | GPR119 (1.00) | GPR119GPR183 | |
| SCHEMBL19449798 | 0.78 | GPR119 (0.63) | GPR119GPR183CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140018380-A1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 RECEPTOR AGONISTS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2014-01-16 | — | — | US | disclosed |
| US-20140018380-A1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 RECEPTOR AGONISTS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2014-01-16 | — | — | US | disclosed |
| EP-2670746-A1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 RECEPTOR AGONISTS | Centaurus Biopharma Co., Ltd. (CN) | 2013-12-11 | — | — | EP | disclosed |
| WO-2012103806-A1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 RECEPTOR AGONISTS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2012-08-09 | — | — | WO | disclosed |
| CN-102617548-A | Bicycloheteroaryl compounds as GPR Receptor stimulant, compositions and application thereof | BEIJING CENTAURUS BIOPHARMA TECHNOLOGY CO LTD | 2012-08-01 | — | — | CN | disclosed |
| WO-2011147951-A1 | CYCLOAMINO DERIVATIVES AS GPR119 ANTAGONISTS | PROSIDION LIMITED (GB) | 2011-12-01 | — | — | WO | disclosed |
| WO-2009125434-A2 | OXIME DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018380-A1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 RECEPTOR AGONISTS | GPR119, GPR88, GPR84 | GPR119 1/4885GPR183 25/4885CYP3A4 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.